6 completed, 4 terminated, 2 withdrawn. 12 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 6, Terminated 4, Withdrawn 2 |
| Phase 2 | 7 | Terminated 4, Completed 3 |
Follow bempegaldesleukin: new trials by email Literature Review of bempegaldesleukin trials Research Report on bempegaldesleukin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 15 | 2021-06-03 | 2023-03-24 |
| A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Bempegaldesleukin, Standard of Care, Placebo - Covid-19, Coronavirus Disease 2019 | Phase 1 | Completed | Nektar Therapeutics | 30 | 2020-11-13 | 2024-03-12 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Pfizer | 3 | 2019-12-30 | 2021-10-14 |
| A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C - Metastatic Melanoma | Phase 1 | Withdrawn | Nektar Therapeutics | 2019-08-01 | 2021-07-08 | |
| Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B) - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | Parker Institute for Cancer Immunotherapy | 43 | 2019-06-21 | 2024-04-12 |
| An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors NKTR-214, Nivolumab - Advanced Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 3 | 2019-04-09 | 2021-10-04 |
| A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) TAK-659, NKTR-214 - Lymphoma, Non-Hodgkin | Phase 1 | Withdrawn | Calithera Biosciences, Inc | 2019-04-03 | 2023-02-08 | |
| A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer VB10.NEO, Bempegaldesleukin - Locally Advanced or Metastatic Solid Tumours | Phase 1 / Phase 2 | Completed | Nykode Therapeutics ASA | 41 | 2018-04-04 | 2023-04-21 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies NKTR-262, bempegaldesleukin, nivolumab - Melanoma, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Nektar Therapeutics | 64 | 2018-03-15 | 2023-03-08 |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors NKTR-214, Pembrolizumab, Cisplatin - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Nektar Therapeutics | 162 | 2017-06-09 | 2023-03-10 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab - Melanoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Nektar Therapeutics | 557 | 2016-12-19 | 2023-03-13 |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors NKTR-214 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Completed | Nektar Therapeutics | 28 | 2015-12-01 | 2021-07-29 |
Melanoma (5) · Carcinoma, Renal Cell (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · COVID-19 (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Transitional Cell (1) · Ependymoma (1) · Glioma (1) · Leukemia (1)
Nektar Therapeutics (6) · Bristol-Myers Squibb (2) · Calithera Biosciences, Inc (1) · Nykode Therapeutics ASA (1) · Parker Institute for Cancer Immunotherapy (1) · Pfizer (1)
United States (10) · Spain (4) · France (3) · Germany (3) · Australia (2) · Belgium (2) · Canada (2) · Italy (2) · Poland (2) · Japan (1) · United Kingdom (1)
PMID 41811823, PMID 30988166, PMID 33298619, PMID 34255535, PMID 34311780, PMID 35444059, PMID 35643589
2016 (1), 2018 (1), 2019 (1)